Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
Cullinan Therapeutics will present initial Phase 1 clinical data for CLN-978, a subcutaneous CD19xCD3 bispecific T-cell engager, at the EULAR 2026 Congress in London. The data covers two ongoing studies, OUTRACE RA and OUTRACE SLE, evaluating the drug in treatment-refractory rheumatoid arthritis and systemic lupus erythematosus, respectively.
Key figures
- Drug Name
- CLN-978
- Phase Of Trial
- Phase 1
- Molecular weight
- 65 kDa
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.